Pneumoconiosis medical therapy

Jump to navigation Jump to search

Pneumoconiosis Microchapters


Patient Information


Historical Perspective




Differentiating Pneumoconiosis from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings


Chest X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pneumoconiosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Pneumoconiosis medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pneumoconiosis medical therapy

CDC on Pneumoconiosis medical therapy

Pneumoconiosis medical therapy in the news

Blogs on Pneumoconiosis medical therapy

Directions to Hospitals Treating Pneumoconiosis

Risk calculators and risk factors for Pneumoconiosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD


There is no treatment for pneumoconiosis; the mainstay of therapy is supportive care, managing complications and monitoring the progress of the disease. Patients should stop smoking, get vaccinated and limit their exposure to the cause of their condition. [1]

Medical Therapy

There is no effective drug treatment for most pneumoconiosis. Cases that have progressed can be administered oxygen and severe cases would benefit from lung transplants. Asbestosis is also associated with lung cancer with an increased risk if the patient smokes and therefore patients are advised to quit smoking. It is important to advise the patient's occupation of their exposure and prevent it further with the availability of personal protective equipment. Patients should be vaccinated against influenza and pneumococcus and offered bronchodilators. [2] [1] [3] [4] [5]


  1. 1.0 1.1 Cookson W, De Klerk N, Musk AW, Glancy JJ, Armstrong B, Hobbs M (1986). "The natural history of asbestosis in former crocidolite workers of Wittenoom Gorge". Am Rev Respir Dis. 133 (6): 994–8. doi:10.1164/arrd.1986.133.6.994. PMID 3013058.
  2. Hayes D, Hayes KT, Hayes HC, Tobias JD (2015). "Long-Term Survival After Lung Transplantation in Patients with Silicosis and Other Occupational Lung Disease". Lung. 193 (6): 927–31. doi:10.1007/s00408-015-9781-z. PMID 26267595.
  3. Pelucchi C, Pira E, Piolatto G, Coggiola M, Carta P, La Vecchia C (2006). "Occupational silica exposure and lung cancer risk: a review of epidemiological studies 1996-2005". Ann Oncol. 17 (7): 1039–50. doi:10.1093/annonc/mdj125. PMID 16403810.
  4. Wilt JL, Banks DE, Weissman DN, Parker JE, Vallyathan V, Castranova V; et al. (1996). "Reduction of lung dust burden in pneumoconiosis by whole-lung lavage". J Occup Environ Med. 38 (6): 619–24. doi:10.1097/00043764-199606000-00014. PMID 8794962.
  5. Sood A (2009). "Current treatment of chronic beryllium disease". J Occup Environ Hyg. 6 (12): 762–5. doi:10.1080/15459620903158698. PMC 2774897. PMID 19894178.

Template:WH Template:WS